Intellia Therapeutics (NTLA) Competitors

Intellia Therapeutics (NASDAQ:NTLA) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Does the media refer more to NTLA or BEAM?

In the previous week, Intellia Therapeutics had 12 more articles in the media than Beam Therapeutics. MarketBeat recorded 23 mentions for Intellia Therapeutics and 11 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 0.34 beat Intellia Therapeutics' score of 0.17 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intellia Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beam Therapeutics	0 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is NTLA or BEAM more profitable?

Beam Therapeutics has a net margin of -661.31% compared to Intellia Therapeutics' net margin of -908.48%. Beam Therapeutics' return on equity of -43.15% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-908.48%	-57.48%	-45.04%
Beam Therapeutics	-661.31%	-43.15%	-31.06%

Which has preferable earnings and valuation, NTLA or BEAM?

Beam Therapeutics has higher revenue and earnings than Intellia Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$52.86M	22.32	-$519.02M	-$4.69	-2.34
Beam Therapeutics	$63.52M	28.38	-$376.74M	-$4.50	-3.96

Which has more risk and volatility, NTLA or BEAM?

Intellia Therapeutics has a beta of 2.31, indicating that its share price is 131% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.22, indicating that its share price is 122% more volatile than the S&P 500.

Do analysts rate NTLA or BEAM?

Intellia Therapeutics currently has a consensus price target of $29.05, indicating a potential upside of 164.36%. Beam Therapeutics has a consensus price target of $48.45, indicating a potential upside of 171.91%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Beam Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.58
Beam Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	3.07

Do institutionals and insiders believe in NTLA or BEAM?

88.8% of Intellia Therapeutics shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 3.1% of Intellia Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Beam Therapeutics beats Intellia Therapeutics on 13 of the 17 factors compared between the two stocks.